
Tenon Medical, Inc.
100
Recent developments include Q3 2026 earnings reporting revenue of $1.4 million and net loss, completion of a warrant inducement offering raising approximately $2.87 million, and entering a waiver agreement to expand the at-the-market offering program.
- Tenon Medical reported third quarter 2026 revenue of $1.4 million and a net loss of $6.639 million with EPS of -$5.39 per share [N2][S2].
- The company secured approximately $2.87 million through a warrant inducement offering in September 2026 [N4].
- In October 2026, Tenon Medical entered a waiver agreement to expand its at-the-market offering program [N3].
- Recent earnings calls provided updates on financial performance and strategic progress [N1][N5][N8].
Tenon Medical, Inc. develops and commercializes medical devices for the treatment of sacroiliac (SI) joint disorders, a significant cause of chronic lower back pain. The company’s primary products are the Catamaran® SI Joint Fusion System and the SImmetry +® SI Joint Fusion System, both designed to provide minimally invasive surgical solutions that promote authentic arthrodesis and durable fixation. The Catamaran System, cleared by the FDA in 2018 and launched nationally in 2022, features a single titanium implant with a unique inferior-posterior approach and proprietary instrumentation. The SImmetry + System, acquired in 2025, offers a lateral access approach with implants and instruments designed for rigid fixation and bone graft delivery. Tenon targets a large U.S. market opportunity estimated at 270,000 annual procedures, with current surgical penetration low at 5-7%, indicating significant market potential. The company emphasizes clinical outcomes, safety, ease of use, and comprehensive training to drive adoption. Financially, Tenon reported $1.432 million in revenue and a net loss of $6.639 million for Q3 2026, with a solid liquidity position. Recent capital raises include private placements and warrant inducement offerings to support operations and growth initiatives. The company’s stock faces Nasdaq minimum bid price compliance challenges but remains listed and is evaluating options to regain compliance.
Tenon Medical, Inc. is a medical device company specializing in sacroiliac joint fusion systems, notably the Catamaran and SImmetry + platforms. The company targets a large, underserved U.S. market for SI Joint surgical interventions estimated at 270,000 procedures annually. Its products emphasize minimally invasive approaches with proprietary implants and instrumentation supported by clinical evidence. As of September 30, 2026, Tenon reported $1.432 million in quarterly revenue and a net loss of $6.639 million, with a strong liquidity position reflected in a current ratio of 2.93. Recent financing activities include a $2.87 million warrant inducement offering and an expanded at-the-market offering program. The company faces Nasdaq listing compliance challenges related to its stock price but remains listed and is pursuing compliance options. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Tenon Medical’s multi-approach SI Joint fusion portfolio addresses a large, underserved market with significant clinical need. Its proprietary implant designs and minimally invasive surgical techniques supported by clinical evidence may facilitate broader physician adoption and patient outcomes. The company’s recent capital raises provide liquidity to support commercialization efforts. Continued expansion of procedure volumes and market share could enhance its position in the growing SI Joint fusion market. The combination of differentiated technology, clinical validation, and targeted training programs supports potential for increased adoption and revenue growth.
The company faces challenges including ongoing net losses and the need for continued capital to fund operations. Nasdaq listing compliance issues related to minimum bid price pose risks to stock liquidity and investor confidence. The SI Joint fusion market is competitive with established orthopedic device companies, and adoption rates remain relatively low due to diagnostic complexity and surgical procedure challenges. Execution risks include scaling commercial operations, physician adoption, and reimbursement dynamics. Clinical outcomes and safety must continue to meet expectations to sustain market acceptance. Market penetration and revenue growth may be constrained by these factors.
Tenon Medical’s competitive moat is built on its differentiated multi-platform portfolio addressing the SI Joint fusion market with two distinct minimally invasive surgical approaches: the Catamaran System’s inferior-posterior approach and the SImmetry + System’s lateral access approach. Proprietary implant designs, instrumentation, and radiographic placement protocols enhance procedural safety and ease of adoption. The company’s focus on authentic arthrodesis supported by clinical and radiographic evidence, along with comprehensive physician training and intellectual property, strengthens its market position. The relatively low penetration of surgical solutions in the SI Joint market and Tenon’s targeted approach to address unmet clinical needs contribute to its competitive advantage. However, the company operates in a competitive environment with larger orthopedic device companies and must continue innovation and execution to maintain differentiation.
• Nasdaq Listing Compliance Risk: The company’s common stock has not maintained the minimum bid price required by Nasdaq, risking potential delisting if compliance is not regained within allowed periods [S1].
• Financial Losses and Capital Needs: Tenon reported net losses and negative EPS, indicating ongoing need for capital to fund operations and commercialization efforts [S2].
• Market Adoption and Competition: The SI Joint fusion market is competitive with established players; adoption rates are currently low due to procedural complexity and diagnostic challenges [S1].
• Execution Risk: Scaling sales, training, and clinical adoption of new surgical systems involves operational risks that could impact growth and market penetration [S1].
Business trends: Expansion of minimally invasive SI Joint fusion systems with clinical evidence targeting a large underserved market.
Execution milestones: Commercial launch of Catamaran System, acquisition of SImmetry + System, recent capital raises, and clinical study initiations.
Key risks: Nasdaq listing compliance, ongoing net losses requiring capital, competitive market dynamics, and execution risks in scaling adoption.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Tenon Medical, Inc. is a medical device company focused on treating sacro-pelvic disorders, specifically sacroiliac (SI) joint dysfunction and pain [S1].
- The company offers two main systems for SI Joint treatment: The Catamaran® SI Joint Fusion System and the SImmetry +® SI Joint Fusion System [S1].
- The Catamaran System received FDA clearance in 2018 and was nationally launched in October 2022, targeting primary SI Joint procedures, revision procedures, and SI Joint fusion adjunct to spine fusion constructs [S1].
- The SImmetry + System was acquired in August 2025 and provides a minimally invasive lateral access approach incorporating orthopedic fusion principles [S1].
- The Catamaran System features a single robust titanium implant with proprietary instruments and a unique inferior-posterior approach designed to reduce morbidity and facilitate bone fusion, supported by clinical and radiographic evidence [S1].
- The company has developed proprietary radiographic placement protocols including 2D and 3D navigation to enhance safety and ease of procedure adoption [S1].
- Tenon Medical estimates a U.S. market opportunity of approximately 270,000 SI Joint surgical procedures annually, representing about a $2.1 billion market [S1].
- Current market penetration for surgical SI Joint solutions is low (5-7%), indicating a largely underserved market [S1].
- The company’s competitive position is strengthened by its multi-platform, multi-approach portfolio with clinical outcomes demonstrating pain reduction, patient satisfaction, and confirmed bone fusion [S1].
- Primary competitive factors include product effectiveness, ease of surgical technique, safety, clinical evidence, sales force quality, training, innovation, intellectual property, and pricing [S1].
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $8.27 million, current assets of $11.22 million, current liabilities of $3.83 million, resulting in a current ratio of 2.93 and cash ratio of 2.29 [S2].
- Revenue for Q3 2026 was $1.432 million with a net loss of $6.639 million and basic and diluted EPS of -$5.39 per share [S2].
- The company completed a private placement and warrant inducement offering raising approximately $2.87 million in September 2026 [N4].
- In October 2026, Tenon Medical entered a waiver agreement to expand its at-the-market offering program [N3].
- The company’s common stock has faced Nasdaq listing compliance issues related to minimum bid price but continues to be listed and is evaluating options to regain compliance [S1].
- Recent earnings calls and reports provide updates on financial performance and strategic progress [N1, N2, N5, N8].
Generated 2026-11-17
- S1 | 2026-03-27 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Tenon Medical (TNON) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tenon-medical-tnon-q3-2026-earnings-call-transcript
- N2 | 2026-11-13 | www.nasdaq.com | Tenon Medical Reports Third Quarter 2026 Revenue of $1.4 Million | https://www.nasdaq.com/articles/tenon-medical-reports-third-quarter-2026-revenue-14-million
- N3 | 2026-10-23 | www.nasdaq.com | Tenon Medical, Inc. Enters Waiver Agreement on October 16, 2026 to Expand At-The-Market Offering | https://www.nasdaq.com/articles/tenon-medical-inc-enters-waiver-agreement-october-16-2026-expand-market-offering
- N4 | 2026-09-15 | www.nasdaq.com | Tenon Medical Secures Approx. $2.87 Mln Through Warrant Inducement Offering; Shares Jump | https://www.nasdaq.com/articles/tenon-medical-secures-approx-287-mln-through-warrant-inducement-offering-shares-jump
- N5 | 2026-08-20 | www.nasdaq.com | Tenon Medical (TNON) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/tenon-medical-tnon-q2-2026-earnings-call-transcript
- N6 | 2026-06-23 | www.nasdaq.com | Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA | https://www.nasdaq.com/articles/top-biotech-gainers-tnon-files-s-1-nvct-inks-license-deal-fth-watch-rgnx-resubmit-bla
- N7 | 2026-03-28 | www.nasdaq.com | Tenon Medical’s Q3 2024 Earnings and Strategic Progress | https://www.nasdaq.com/articles/tenon-medicals-q3-2024-earnings-and-strategic-progress
- N8 | 2026-03-19 | www.nasdaq.com | Tenon Medical (TNON) Q4 2025 Earnings Transcript | https://www.nasdaq.com/articles/tenon-medical-tnon-q4-2025-earnings-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


